Serum Soluble Epidermal Growth Factor Receptor Level Increase in Patients Newly Diagnosed with Type 2 Diabetes Mellitus

• Published in: Diabetes & metabolism journal Vol. 42; no. 4; pp. 343 - 347
• Main Authors: Kim, Ji Min, Choung, Sorim, Joung, Kyong Hye, Lee, Ju Hee, Kim, Hyun Jin, Ku, Bon Jeong
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Diabetes Association / Daehan Dangnyobyeong Hakoe 01.08.2018; Korean Diabetes Association; 대한당뇨병학회
• Subjects: Apolipoproteins; Biobanks; Biological assay; Body mass index; Brief Report; Cancer; Cardiovascular disease; Cholesterol; Conflicts of interest; Creatinine; Diabetes; Diabetes mellitus, type 2; Enzymes; Epidermal growth factor; Glucose; Hemoglobin; High density lipoprotein; Hospitals; Hypertension; Insulin resistance; Kinases; Medical prognosis; Metabolism; Peptides; Plasma; Receptor, epidermal growth factor; Regression analysis; 내과학; Diabetes mellitus, type 2; Biological assay; Receptor, epidermal growth factor
• ISSN: 2233-6079; 2233-6087
• DOI: 10.4093/dmj.2017.0082

We analyzed circulating soluble epidermal growth factor receptor (sEGFR) levels in humans. Serum sEGFR levels were higher in subjects with newly diagnosed type 2 diabetes mellitus compared with controls. Serum sEGFR was positively correlated with glycosylated hemoglobin and serum glucose and negatively correlated with serum insulin and C-peptide levels.